Drug Information

Drug General Information
Drug ID
D0X2UI
Former ID
DIB012317
Drug Name
LIK-066
Indication Type 2 diabetes [ICD9: 250; ICD10:E11] Phase 2 [524252]
Company
Novartis AG
Target and Pathway
Target(s) Sodium/glucose cotransporter 1 Target Info Inhibitor [543973]
KEGG Pathway Carbohydrate digestion and absorption
Bile secretion
Mineral absorption
PathWhiz Pathway Lactose Degradation
Trehalose Degradation
Reactome Hexose transport
Na+-dependent glucose transporters
Inositol transporters
WikiPathways NRF2 pathway
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds
Metabolism of carbohydrates
References
Ref 524252ClinicalTrials.gov (NCT01824264) Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With Diabetes. U.S. National Institutes of Health.
Ref 543973(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 915).

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.